Comparing everyday treatments for higher-risk pulmonary embolism
Compares clot treatments in people with higher-risk pulmonary embolism.
Key facts
- Who runs it
- Nanjing First Hospital, Nanjing Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism
- Status
- Not yet recruiting
- People taking part
- 1,300 people, planned
- Started
- 1 Jun 2026
- Expected to end
- 31 Dec 2029
- Type of study
- Observational, 3 groups
- Treatments tested
- Anticoagulants
- Thrombolytic Agents
- Mechanical Thrombectomy Devices
- Record updated
- 22 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with a sudden blood clot in the lungs (acute pulmonary embolism) at intermediate-high risk who have stable blood pressure. It compares anticoagulation, thrombolysis and mechanical thrombectomy in real-world care in China.
- Age
- No age limit.
- Sex
- All sexes can join.
- Disease stage
- Acute pulmonary embolism confirmed by CTPA in the main or lobar lung arteries, with symptoms for ≤ 14 days. It must be intermediate-high risk: RV/LV ratio ≥ 0.9, raised heart markers, and stable circulation (SBP ≥ 90 mmHg, no drugs needed to support blood pressure).
- Earlier treatment
- People cannot join if they already had thrombolysis or mechanical thrombectomy for this clot before enrolment.
- Biomarker or test result
- RV/LV ratio ≥ 0.9 by CT or echocardiography. Raised heart markers: Troponin > 99th percentile or BNP > 100 pg/mL.
Main reasons for not taking part
- Already had thrombolysis or mechanical thrombectomy for the current clot
- Unable to have CTPA imaging at the start or at follow-up
- Unable to give informed consent or complete follow-up
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age unlimited (reflecting real-world population)
- Symptom duration of acute PE ≤ 14 days
- Confirmed acute PE by CTPA involving main or lobar pulmonary arteries
- Defined as Intermediate-High Risk PE meeting all of the following:
- RV/LV ratio ≥ 0.9 (by CT or Echocardiography)
- Elevated cardiac biomarkers (Troponin > 99th percentile or BNP > 100 pg/mL)
- Hemodynamically stable (SBP ≥ 90 mmHg, no vasopressors required)
- Able to provide informed consent and complete follow-up
Who cannot take part
- Already received thrombolysis or mechanical thrombectomy for the current episode prior to enrollment
- (Note: Unlike strict RCTs, patients with cancer, renal insufficiency, or advanced age are NOT excluded to ensure real-world representativeness)
- Unable to obtain baseline or follow-up CTPA imaging
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to compare the effectiveness and safety of three treatment strategies (Anticoagulation, Thrombolysis, and Mechanical Thrombectomy) for patients with intermediate-high risk acute pulmonary embolism (PE) in a real-world setting. Approximately 1,300 patients will be enrolled across multiple centers in China. Patients will be followed for 90 days to assess mortality, heart function recovery, bleeding risks, and quality of life. The results will help guide personalized treatment decisions and healthcare policy.
The 3 groups in the trial
- Anticoagulation Cohort
Patients receiving standard anticoagulation therapy alone without thrombolysis or mechanical thrombectomy.
Treatment: Anticoagulants
- Thrombolysis Cohort
Patients receiving systemic thrombolysis or catheter-directed thrombolysis.
Treatment: Mechanical Thrombectomy Devices
- Mechanical Thrombectomy Cohort
Patients undergoing mechanical thrombectomy procedures using percutaneous devices.
Treatment: Thrombolytic Agents
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Real-World Comparative Effectiveness and Safety of Anticoagulation, Thrombolysis, and Mechanical Thrombectomy in Intermediate-Risk Acute Pulmonary Embolism: A Multicenter Prospective Cohort Study
- Plain-language title
- Comparing everyday treatments for higher-risk pulmonary embolismGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 22 May 2026